Literature DB >> 17169036

The non-peptidic HIV protease inhibitor tipranavir and two synthetic peptidomimetics (TS98 and TS102) modulate Pneumocystis carinii growth and proteasome activity of HEL299 cell line.

Francesca Mazza1, Elisa Tronconi, Antonella Valerio, Marcus Groettrup, Marcel Kremer, Alessandro Tossi, Fabio Benedetti, Antonietta Cargnel, Chiara Atzori.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17169036     DOI： 10.1111/j.1550-7408.2006.00208.x

Source DB:  PubMed          Journal:  J Eukaryot Microbiol        ISSN： 1066-5234            Impact factor:   3.346


× No keyword cloud information.
  2 in total

1.  Role of tipranavir in treatment of patients with multidrug-resistant HIV.

Authors:  Joshua D Courter; Colleen J Teevan; Michael H Li; Jennifer E Girotto; Juan C Salazar
Journal:  Ther Clin Risk Manag       Date:  2010-10-05       Impact factor: 2.423

Review 2.  Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.

Authors:  Huanjie Yang; Xin Chen; Kai Li; Hassan Cheaito; Qianqian Yang; Guojun Wu; Jinbao Liu; Q Ping Dou
Journal:  Semin Cancer Biol       Date:  2019-12-26       Impact factor: 15.707
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.